Metropolis Healthcare Ltd (METROPOLIS) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Metropolis Healthcare delivered strong 11% year-on-year revenue growth in Q3 FY25, driven by a 4.1% increase in patient volumes and a 6.5% contribution from adjustments in product mix and pricing.
- Excluding institutional business, revenue grew by approximately 13% year-on-year.
- The B2C portfolio maintained momentum with 15% year-on-year growth, driven by TruHealth (25% growth) and Specialty testing (20% growth).
- B2C now represents 55% of total revenue, a 200 basis point improvement.
- Maharashtra demonstrated strong performance with 16% B2C revenue growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.